If the price of semaglutide is cut in half, it might become a good value for treating people with heart disease who are overweight or obese—even if they don’t have diabetes—because it could add...
Evidence from Studies
Supporting (1)
0
Community contributions welcome
0
Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
Computational/Algorithm Study
2025 JanContradicting (0)
0
Community contributions welcome
No contradicting evidence found
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.